Supplementary Figures for Ishii et al.

Obesity-promoting and anti-thermogenic effects of neutrophil gelatinase-associated lipocalin in mice

Akira Ishii¹, Goro Katsuura², Hirotaka Imamaki^{1,3}, Hiroyuki Kimura⁴, Keita P. Mori¹,

Takashige Kuwabara⁵, Masato Kasahara⁶, Hideki Yokoi¹, Kousaku Ohinata⁷,

Tomoko Kawanishi⁸, Junichi Tsuchida^{9,10}, Yuji Nakamoto¹¹, Kazuwa Nakao¹²,

Motoko Yanagita^{1,9}, Masashi Mukoyama⁵ & Kiyoshi Mori^{9,13,14}

¹Department of Nephrology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

²Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.

³Department of Nephrology, Hirakata Kohsai Hospital, Hirakata, Japan.

⁴Department of Analytical and Bioinorganic Chemistry, Kyoto Pharmaceutical University, Kyoto, Japan.

⁵Department of Nephrology, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

⁶Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan.


⁷Division of Food Science and Biotechnology, Graduate School of Agriculture, Kyoto University, Uji, Japan. ⁸Department of Nephrology, Ohkubo Hospital, Tokyo, Japan.

⁹TMK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan. ¹⁰Research Unit/Nephrological & Endocrinological Science, Sohyaku, Innovative Research Division, Mitsubishi Tanabe Pharma Corporation, Toda, Japan.

¹¹Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.


¹²TK Project, Medical Innovation Center, Kyoto University Graduate School of Medicine, Kyoto, Japan.
¹³Department of Molecular and Clinical Pharmacology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan.

¹⁴Department of Nephrology and Kidney Research, Shizuoka General Hospital, Shizuoka, Japan. Correspondence and requests for materials should be addressed to K.M. (kiyoshimori2001@gmail.com)




Supplementary Figure S1. Body weights of *Lcn2* KO and WT male mice treated with ND or HFD since 8 weeks of age.

Body weights were significantly elevated after 4 weeks of treatment in all 4 groups compared to 0 week, respectively (P < 0.05, n = 4-8).




Supplementary Figure S2. Locomotor activity of *Lcn2* KO and WT female mice.

After 24 weeks of (a) HFD or (b) ND treatment, hourly (left) and cumulative (right) locomotor activities were examined (n = 4).




Supplementary Figure S3. Gene expression of beige marker *Ucp1* in WAT of *Lcn2* KO and WT mice after ND or HFD feeding.

After 24 weeks of HFD or ND treatment, *Ucp1* mRNA expression was examined in periovular and mesenteric WAT (n = 4-5). Gene expression level was normalized for 18S ribosomal RNA expression. The level in periovular WAT of WT mice given ND was defined as 100(%). #P < 0.05 vs ND.




Supplementary Figure S4. *Lcn2* mRNA expression in organs of WT mice after cold exposure.

Lcn2 mRNA expression levels at 4 hours after 4°C or 23°C treatment (n = 4). The level in Mes WAT at 23°C was defined as 1.0.




Supplementary Figure S5. Noradrenaline content in BAT after 4 h cold exposure in *Lcn2* KO, WT and WT Tg mice (n = 5). $\#P < 0.05 \text{ vs } 23^{\circ}\text{C}$. *P < 0.05 vs WT.

BAT noradrenaline (μ g/g tissue)



Supplementary Figure S6. Effects of apo-LCN2 (siderophore-free and iron-free LCN2) upon cold tolerance in Lcn2 KO mice (n = 6).



Supplementary Figure S7. *Slc22a17* and *Adrb3* mRNA expression in BAT of *Lcn2* KO and WT mice after cold exposure or HFD treatment

BAT was collected after 4 h of cold exposure or 24 weeks of HFD (n = 4-6). The level in WT BAT at 23°C given ND was defined as 100(%). #P < 0.05 vs 23°C.